Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20050181053 A1
Publication typeApplication
Application numberUS 11/096,457
Publication date18 Aug 2005
Filing date1 Apr 2005
Priority date20 Nov 2000
Also published asCA2359812A1, CA2359812C, US6893662, US8580302, US9089492, US20020098235, US20050169996, US20140093576
Publication number096457, 11096457, US 2005/0181053 A1, US 2005/181053 A1, US 20050181053 A1, US 20050181053A1, US 2005181053 A1, US 2005181053A1, US-A1-20050181053, US-A1-2005181053, US2005/0181053A1, US2005/181053A1, US20050181053 A1, US20050181053A1, US2005181053 A1, US2005181053A1
InventorsGregory Dittmar, Joseph Amante, Tony Cronk, Daniel Newby
Original AssigneeThe Procter & Gamble Company
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US 20050181053 A1
Abstract
The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent. This invention further relates to a method of maintaining the desired site of delivery of a therapeutic agent in the gastrointestinal tract by administering the above compositions to a human or lower animal.
Images(9)
Previous page
Next page
Claims(20)
1-24. (canceled)
25. A pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising:
a. a safe and effective amount of a therapeutically active agent;
b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and
c. an outer coating layer having a minimum thickness from about 10 μm to about 200 μm, applied to the inner coating layer, said outer coating layer comprising a film coating material selected from the group consisting of cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropyl methylcellulose, wax, carnauba wax, fatty alcohols, hydrogenated vegetable oils, zein, shellac, sucrose, Arabic gum, polyethylene glycol, polyvinylpyrolidone, gelatin, sodium alginate, dextrin, psyllium husk powder, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, and compatible mixtures thereof;
wherein the solid unit dosage form has a total weight from about 550 mg to about 1500 mg; and
wherein the inner coating layer and the outer coating layer contain no therapeutically active agent.
26. The composition of claim 25 wherein the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:2.
27. The composition of claim 25 wherein the film coating material is selected from the group consisting of cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropyl methylcellulose, wax, carnauba wax, Arabic gum, polyethylene glycol, polyvinylpyrolidone, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, and compatible mixtures thereof.
28. The composition of claim 27 wherein the film coating material is selected from the group consisting of cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and compatible mixtures thereof.
29. The composition of claim 28 wherein the film coating material is a mixture of hydroxypropyl cellulose and hydroxypropyl methylcellulose.
30. The composition of claim 25 wherein the therapeutically active agent is selected from the group consisting of laxatives, anti-diarrheals, nonsteroidal anti-inflammatory agents, glucocorticoids, antimicrobials, immunosuppressants, chemotherapeutics or anti-cancer drugs, peptides, proteins, cardiovascular drugs, psychotropic drugs, H2-blockers, antiasthmatic agents, and antihistamines.
31. The composition of claim 30 wherein the therapeutically active agent is a nonsteroidal anti-inflammatory agent.
32. The composition of claim 31 wherein the nonsteroidal anti-inflammatory agent is 5-amino salicylic acid or a pharmaceutically acceptable salt or ester thereof.
33. The composition of claim 32 wherein the 5-amino salicylic acid or pharmaceutically acceptable salt or ester thereof is present in an amount from about 700 mg to about 900 mg per solid unit dosage form.
34. The composition of claim 25 wherein the outer coating layer has a minimum thickness from about 30 μm to about 150 μm.
35. The composition of claim 25 wherein the total coating thickness of the inner and outer coating layers combined is from about 5 mg/cm2 to about 40 mg/cm2.
36. The composition of claim 35 wherein the total coating thickness is from about 10 mg/cm2 to about 15 mg/cm2.
37. The composition of claim 25 wherein the solid dosage form is coated by continuous spray methods wherein the outer coating layer is applied after the inner coating layer but before the inner coating layer is dried or cured.
38. The composition of claim 25 wherein the solid unit dosage form has a total weight from about 600 mg to about 1200 mg.
39. The composition of claim 38 wherein the solid unit dosage form has a total weight from about 750 mg to about 1000 mg.
40. The composition of claim 25 wherein the solid dosage form is a compressed tablet.
41. A method of consistent and reliable delivery and release of a therapeutically active agent to the desired region of delivery by orally administering the composition of claim 25.
42. A pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising:
a. a safe and effective amount of 5-amino salicylic acid;
b. an inner coating layer comprising poly(methacrylic acid, methyl methacrylate) 1:2; and
c. an outer coating layer having a minimum thickness from about 10 μm to about 200 μm, applied to the inner coating layer, said outer coating layer comprising a mixture of hydroxypropyl cellulose and hydroxypropyl methylcellulose.
43. A method of consistent and reliable delivery and release of 5-amino salicylic acid to the desired region of delivery by orally administering the composition of claim 42.
Description
    CROSS REFERENCE TO RELATED APPLICATION
  • [0001]
    This application claims the benefit of U.S. Provisional Application No. 60/252,122, filed Nov. 20, 2000.
  • TECHNICAL FIELD
  • [0002]
    The present invention relates to novel unit dosage forms comprising therapeutic agents with improved resistance to coating fractures during processing, manufacturing or packaging.
  • BACKGROUND OF THE INVENTION
  • [0003]
    A number of prior art references teaches the advantages of delivery of therapeutic agents to the lower part of the gastrointestinal tract, especially the large intestine or the colon. These reference illustrate the difficulty of formulating dosage forms that will achieve this delivery benefit. For example, U.S. Pat. Nos. 5,541,170 and 5,541,171, Rhodes et al., both issued Jul. 30, 1996, discuss the delivery of pharmacologically active agents, especially 5-aminosalicylic acid, to the large intestine for the treatment of colonic or rectal disorders. U.S. Pat. No. 5,686,105, Kelm et al., issued Nov. 11, 1997, teaches colonic delivery of therapeutic agents wherein the dosage form comprises a coating system with at least one inner coating layer and one outer coating layer. The inner coating layer is an enteric polymer that begins to dissolve in an aqueous media at a pH between about 5 to about 6.3, and the outer coating layer is an enteric polymer that begins to dissolve in an aqueous media at a pH of between about 6.8 to 7.2. U.S. Pat. No. 5,171,580, Iamartino et al., issued Dec. 15, 1992, teaches pharmaceutical preparations containing an active ingredient to be released in the lower part of the gastrointestinal tract, the large intestine and especially the colon, consisting of a core with the active, the core being coated with three protective layers at different solubilities. This reference focuses on providing more specific and reliable release of a therapeutic active agent to the lower part of the gastrointestinal tract, especially the colon, achieved with the three protection layers, as well as the benefits of having a selective effect in the colon. Other prior art references also focus on the benefits of delivering therapeutic agents to the colon. These references include U.S. Pat. No. 5,686,106, Kelm et al., issued Nov. 11, 1997; U.S. Pat. No. 5,914,132, Kelm et al, issued Jun. 22, 1999; U.S. Pat. No. 4,910,021. Davis et al, issued Mar. 20, 1990: U.S. Pat. No. 4,432,966, Zeitoun et al., issued Feb. 21, 1984; U.S. Pat. No. 5,654,004, Okayama et al., issued August 5, 1997; U.S. Pat. No. 5,900,252, Calcanchi et al., issued May 4, 1999; U.S. Pat. No. 5,482,718, Shah et al, issued Jan. 9, 1996; U.S. Pat. No. 5,316,772, Jurgens et al., issued May 31, 1994; EP 225,189, Davies, et al, published Jun. 10, 1987; and Khan et al., Drug Development and Industrial Pharmacy, 26(5), 549-554 (2000).
  • [0004]
    None of the above prior art references, however, discusses the problem or possibility of coating fractures that may occur during processing, manufacturing, or packaging of the oral unit dosage form. Coating fractures may cause unreliable or inconsistent delivery or release of the therapeutic agent to the desired region of the gastrointestinal tract. These fractures may be associated with premature rupture or release of the unit dosage forms. Indeed, coating fractures may especially be problematic for larger than average size unit dosage forms or heavier unit dosage forms resulting from using larger dosages/levels of the therapeutic active.
  • [0005]
    The present invention, therefore, relates to solid unit dosage forms for oral administration in humans or lower animals which minimizes the impact or negative effects of coating fractures, especially for larger or heavier unit dosage forms. By reducing these negative effects, these compositions maintain the desired site of delivery of the therapeutic agents in the gastrointestinal tract.
  • SUMMARY OF THE INVENTION
  • [0006]
    The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising:
      • a. a safe and effective amount of a therapeutically active agent;
      • b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and
      • c. an outer coating layer comprising an enteric polymer or film coating material;
        wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer contain no therapeutically active agent.
  • [0010]
    In another embodiment the present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising:
      • a. a safe and effective amount of a therapeutically active agent;
      • b. an inner coating layer comprising poly(methacrylic acid, methyl methacrylate) 1:2: and
      • c. an outer coating layer comprising an enteric polymer or film coating material;
        wherein the inner coating layer is not the same as the outer layer coating. This invention further relates to a method of maintaining the desired site of delivery of a therapeutic agent in the gastrointestinal tract by reducing the impact of coating fractures, through administering the above compositions to a human or lower animal.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0014]
    The phrase “safe and effective amount”, as used herein, means an amount of therapeutically active agent or other component of the present compositions, high enough to provide a significant positive modification of the condition to be treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. A safe and effective amount of therapeutically active agent or other component of the present compositions, will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the agent selected and like factors.
  • [0000]
    Therapeutically Active Agent
  • [0015]
    The methods and compositions of the present invention comprise a safe and effective amount of the therapeutically active agent. In one embodiment the therapeutic agents suitable for incorporation into dosage forms of the present invention are those for which treatment of the colon is therapeutically advantageous. These include therapeutic agents useful for the treatment of diseases of the colon such as constipation, diarrhea, irritable bowel syndrome (IBS), Crohn's disease, colitis, ulcerative colitis, carcinomas, idiopathic protitis, infection in which systemic absorption of the therapeutic agent is neither required or desired, and other diseases or disorders of the colon or rectum. These include actives for constipation and laxatives such as picosulfate and sennasides, anti-diarrheals such as loperamide, nonsteroidal anti-inflammatory drugs such as salicylates, indomethacin, ibuprofen, flurbiprofen, naproxen, piroxicam 5-amino salicylic acid (or pharmaceutically acceptable salts or esters thereof), balsalazide as well as agents disclosed in U.S. Pat. No. 4,412,992, Chan, issued Nov. 1, 1983, as well as NSAIDS disclosed in U.S. Pat. No. 4,552,899, Sunshine et al., issued Nov. 12, 1985, steriods such as hydrocortisone, prednisone, prednisolone, prednisolone phosphate, prednisolone metasulpho-benzoate sodium, prednisolone sodium phosphate, beclomethasone dipropionate and beclomethasone valerate, glucocorticoids such as dextramethazone, antimicrobials or antiparasitic agents, (especially those effective against anaerobic microbes such as methotrexate), 5-aminosalicylic compounds, 4-aminosalicylic compounds, sulfasalazine, benzalazine, erythromycin, chloroguine, iodochlorhydroxyquin, disodohydroxyquin, neomycin and tetracyclines, immunosupressants such as cyclosporine A, chemotherapeutics for treatment of carcinomas, gastointestinal stimulants and prokinetic agents such as cisapride, peppermint oil and other carminative essential oils, actives for the removal of excess bile acids such as cholestyramine. The above references are herein incorporated by reference in their entirety.
  • [0016]
    Certain therapeutic agents, particularly peptides and proteins, are subject to lumenal degradation in the stomach and small intestine. The colon may be a preferable site of absorption for such compounds since lumenal enzymatic activity is less in the colon (M. Mackay and E. Tomlinson, in Colonic Drug Absorption and Metabolism, P. R. Bieck, ed., Marcel Dekker, Inc., New York, Basel, Hong Kong, 137-158 (1993)). Peptides and proteins that may exhibit improved systemic bioavailability benefit when released in the colon include calcitonin, insulin, and human growth hormone. In certain cases, the peptide or protein may be formulated with a system than enhances the absorption of the macromolecule (M. Mackay and E. Tomlinson, in Colonic Drug Absorption and Metabolism, P. R. Bieck, ed., Marcel Dekker, Inc., New York, Basel, Hong Kong, 137-158 (1993)).
  • [0017]
    The therapeutically active agents are present in the solid dosage forms in suitable unit dosage amounts. These amounts will be known by those skilled in the art. In one embodiment the active agent is 5-amino salicylic acid or pharmaceutically acceptable salts or esters thereof at a dosage range of from about 400 mg to about 1.5 grams per tablet, in another embodiment is from about 700 mg to about 900 mg per tablet.
  • [0018]
    The therapeutically active agent may be incorporated into one of the several substrates described herein in a manner consistent with the physical chemical properties of the drug and its pharmacodynamics, using techniques known to those skilled in the art.
  • [0000]
    The Inner and Outer Coating Layers
  • [0019]
    In one embodiment the coating layers of the present invention do not contain any therapeutically active agent of the present invention. In addition, the “coating layers” described herein refer to completely encasing or coating all of the solid unit dosage form (does not include coated microcrystal spheres, coated pellets, coated beads, coated microparticles or particles, or coated granules, of the therapeutically active agent).
  • [0000]
    Inner Coating Layer
  • [0020]
    The inner coating layer is selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof. Generally the inner coating layer is selected based on the preferred delivery site desired and is applied to the core of the unit dosage form to achieve a minimum coating thickness from about 20 μm to about 120 μm. The coating thickness depends on the actual size of the unit dosage form, but in one embodiment the minimum coating thickness of the inner coating layer is from about 20 μm to about 50 μm.
  • [0021]
    In one embodiment the inner coating layer comprises poly (methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S), or other enteric polymer material which has the same pH release characteristics in aqueous media as Eudragit® S. Eudragit® S, an anionic copolymer derived from methacrylic acid and methyl methacrylate, with a ratio of free carboxyl groups to the ester groups of approximately 1:2, and a mean molecular weight of approximately 135,000, from Rohm Tech. In one embodiment the inner coating layer is any other polymer with the same aqueous pH release charcteristics as Eudragit® S.
  • [0000]
    Outer Coating Layer
  • [0022]
    The outer coating layer comprises an enteric polymer or film coating material, wherein the inner coating layer is not the same as the outer coating layer. Generally, if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 (Eudragit® L) then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S) or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2. The outer coating material can be any coating material that protects the inner coating layer from fractures during handling and that dissolves or is removed in the gastrointestinal tract prior to the inner coating layer. The outer coating layer is either a single coating or multiple coatings of either an enteric polymer material or film coating material. In another embodiment the unit dosage form has a single outer coating layer. In another embodiment the outer coating layer is an anionic copolymer. In one embodiment the outer coating cannot comprise an enteric polymer or mixtures thereof with the same pH of release in aqueous media as Eudragit® S. If the inner coating is poly(methacrylic acid, methyl methacrylate 1:2, then the outer coating layer can only comprise poly(methacrylic acid, methyl methacrylate 1:2 (Eudragit® S) if it is mixed with another enteric polymer or film coating material such that the pH of release, in aqueous media, for the mixture is less than the pH of release (aqueous media) for poly(methacrylic acid, methyl methacrylate 1:2 (Eudragit® S) alone.
  • [0023]
    In another embodiment the outer coating layer is an enteric polymer material that begins to dissolve in an aqueous media at a pH of less than about 7, in another embodiment at a pH of less than about 6.8. Generally the outer coating layer is applied to the core of the unit dosage form to achieve a minimum thickness of from about 10 μm to about 200 μm, in another embodiment is from about 30 μm to about 150 μm.
  • [0024]
    In one embodiment the outer coating layer is selected from the group consisting of film coatings, cellulose derivatives, cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropyl methylcellulose, wax or wax like substance, such as camauba wax, fatty alcohols, hydrogenated vegetable oils, zein, shellac, sucrose, Arabic gum, polyethylene glycol, polyvinylpyrolidone, gelatin, sodium alginate, dextrin, psyllium husk powder, polymethacrylates, anionic polymethacrylates, poly(methacrylic acid, methyl methacrylate) 1:1, mixtures of poly(methacrylic acid, methyl methacrylate) 1:2 and poly(methacrylic acid, methyl methacrylate) 1:1, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, polyvinyl acetate phthalate, poly(methacrylic acid, ethyl acrylate) 1:1, and compatible mixtures thereof.
  • [0025]
    In another embodiment the outer coating layer is selected from the group consisting of cellulose derivatives, cellulose ethers, methyl cellulose, ethylcellulose, carboxymethylcellulose, carboxymethylethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, low viscosity hydroxypropyl cellulose, low viscosity hydroxypropyl methylcellulose, fatty alcohols, hydrogenated vegetable oils, zein, shellac, sucrose, Arabic gum, polyethylene glycol, polyvinylpyrolidone, gelatin, sodium alginate, dextrin, psyllium husk powder, polymethacrylates, anionic polymethacrylates, poly(methacrylic acid, methyl methacrylate) 1:1, mixtures of poly(methacrylic acid, methyl methacrylate) 1:2 and poly(methacrylic acid, methyl methacrylate) 1:1, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, polyvinyl acetate phthalate, poly(methacrylic acid, ethyl acrylate) 1:1, and compatible mixtures thereof.
  • [0026]
    In another embodiment the outer coating layer is selected from the group consisting of anionic polymethacrylates, poly(methacrylic acid, methyl methacrvlate) 1:1, mixtures of poly(methacrylic acid, methyl methacrylate) 1:2 and poly(methacrylic acid, methyl methacrylate) 1:1, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, polyvinyl acetate phthalate, poly(methacrylic acid, ethyl acrylate) 1:1, and compatible mixtures thereof.
  • [0027]
    In another embodiment the outer coating layer is a single layer of a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 (Eudragit® L) and poly(methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S) in a ratio of about 1:10 to about 1:10, preferably about 1:5 to about 1:3 more preferably about 2:3. The coating thickness depends on the actual size of the unit dosage form, but in one embodiment the minimum coating thickness of the outer coating layer is from about 10 μm to about 50 μm, in another embodiment is from about 20 μm to about 40 μm.
  • [0028]
    In another embodiment the outer coating layer is a single coating of an enteric polymer that begins to dissolve in aqueous media at a pH between about 5 to about 6.3, in another embodiment at a pH between about 5 to about 6, in even another embodiment at a pH between about 5 to about 5.5.
  • [0029]
    In one embodiment, the function of the outer coating layer is to prevent or minimize fractures of the inner coating layer during formulation processing, manufacturing, and packaging, and the function of the inner coating layer is to maintain the desired point of release of the therapeutic active agent in the gastrointestinal tract. For example if the inner coating is poly(methacrylic acid, methyl methacrylate) 1:2 (Eudragit® S), the present invention maintains the desired point of release, as described, for example, in U.S. Pat. Nos. 5,541,170 and 5,541,171, Rhodes et al., which are incorporated herein by reference in their entirety.
  • [0030]
    In one embodiment the total coating thickness (both the inner and outer coating layers together) is from about 5 mg/cm2 to about 40 mg/cm2, in another embodiment is from about 10 mg/cm2 to about 15 mg/cm2.
  • [0031]
    Specific examples of the outer coating layer follow.
    • Eudragit® L, is an anionic copolymer derived from methacrylic acid and methyl methacrylate, with a ratio of free carboxyl groups to the ester groups of approximately 1:1, and a mean molecular weight of approximately 135,000, from Rohm Tech;
    • Eudragit® L 30 D, is an aqueous acrylic resin dispersion, an anionic copolymer derived from methacrylic acid and ethyl acrylate with a ratio of free carboxyl groups to the ester groups of approximately 1:1, and a mean molecular weight of approximately 250,000; (it is supplied as an aqueous dispersion containing 30% w/w of dry lacquer substance);
    • Eudragit® L 100-55, is an anionic copolymer derived from methacrylic acid and ethyl acrylate, with a ratio of free carboxyl groups to the ester groups of approximately 1:1, and a mean molecular weight greater than about 100,000;
    • cellulose acetate phthalate or CAP®, available from Eastman Chemical;
    • cellulose acetate trimelliate, CAT® available from Eastman Chemical;
    • hydroxypropyl methylcellulose phthalate (USP/NF type 220824) HPMCP 50® and (USP/NF type 200731) HPMCP 55® available from Shin Etsu Chemical;
    • polyvinyl acetate phthalate, PVAP®, available from Colorcon;
    • hydroxypropyl methylcellulose acetate succinate, HPMCAS®, available from Shin Etsu Chemical; hydroxypropylcellulose, Klucel®.
  • [0040]
    To enhance the elasticity of the coating materials, preferably the coating material of the present invention also comprises a plasticizer. Appropriate plasticizers include polyethylene glycols, propylene glycols, 1,2-propylene glycol, dibutyl phthalate, diethyl phthalate, tributyl citrate, tributyrin, butyl phthalyl butyl glycolate (Santicizer® B-16, from Monsanto, St. Louis, Mo.), triacetin, castor oil and citric acid esters; in another embodiment the plasitcizer is dibutyl phthalate, tributyl citrate, or triethyl citrate. These plasticizers are present in an amount to facilitate the coating process and to obtain an even coating film with enhanced physical stability. Generally the coating material comprises from about 0% to about 50% of a plasticizer, preferably from about 2% to about 25% by weight, more preferably from about 10% to about 20% by weight of the enteric polymer.
  • [0041]
    In addition, to facilitate the coating process, the coating material may also comprise inert solid particulates. Preferred inert solid particulates include talc and titanium dioxide.
  • [0042]
    The selections of optional plasticizer, optional inert solid particulate, and levels thereof, coating formulation type (solvent, ammoniated aqueous solution, or aqueous dispersion), and process are based upon the specific enteric polymer or film coatings used and the type of dosage form used according to criteria known to those skilled in the art. The solvent for the coating layers may be organic or aqueous. In one embodiment the coating layer is obtained via the use of an aqueous dispersion of the coating material.
  • [0000]
    The Dosage Form and Method of Making the Dosage Form
  • [0043]
    A safe and effective amount of therapeutically active agent is incorporated into a solid unit dosage form. The term “solid unit dosage form” means any dosage form, preferably non-liquid, intended to be swallowed and having a sufficiently defined form to be coated. Solid unit dosage forms may be selected from the group consisting of a hard or soft capsule or a compressed tablet. In one embodiment the solid dosage forms of the present invention are selected from the group consisting of soft gelatin capsules; hard gelatin capsules; and compressed tablets of any size or shape. In one embodiment the unit dosage form of the present invention comprises a unit dosage form from about 550 mg to about 1.5 gram total weight, in another embodiment from about 600 mg to about 1.2 grams total weight, and in even another embodiment from about 750 mg to about 1 gram total weight.
  • [0044]
    In one embodiment the unit dosage form is a spherical or elliptical soft elastic gelatin capsule. The soft elastic gelatin capsule is filled with therapeutically active agent suspended in a suitable vehicle compatible with the soft gelatin capsule.
  • [0045]
    In still another embodiment the unit dosage form is a hard capsule (i.e. starch or gelatin hard. capsule), for example a starch capsule such as Capill® from Capsulgel (Greenwood, S.C.) in which the length of the long axis of the capsule is less than about 10 mm and not more than about 1.5 times greater than the short axis diameter of the capsule. The capsule may be filled with a solid form of therapeutically active agent as described above, or alternatively with therapeutically active agent dissolved or suspended in a suitable vehicle compatible with the capsule wall.
  • [0046]
    In another embodiment the unit dosage form is a compressed spherical or elliptical tablet. The tablet is comprised of a solid form of therapeutically active agent and is compressed using conventional equipment and processes.
  • [0047]
    In addition to the therapeutically active agent the compositions of this invention also generally comprise pharmaceutiacally acceptable excipients. As used herein, “excipient” means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to a subject. The term “compatible”, as used herein, means that the components of the composition are capable of being commingled with the active agent, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the composition under ordinary use situations. Pharmaceutically-accepted excipents must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the subject being treated. Excipients may act to facilitate incorporation of the therapeutically active agent into the dosage form, modify the release of the therapeutically active agent from the dosage form, stabilize the therapeutically active agent. or enhance absorption of the therapeutically active agent. Excipients should be safe for their intended use at the levels employed in the formulation. The formulation of therapeutically active agent and excipients is selected according to criteria well known to those skilled in the art to achieve the desired release rate, stability, absorption, and to facilitate the dosage form manufacture.
  • [0048]
    Some examples of pharmaceutically-acceptable excipients or components thereof are sugars, such as lactose, glucose, and sucrose; starches, such as cornstarch, potato starch, and sodium starch glycolate at a level of about 1% to about 8% by weight, in another embodiment from about 2% to about 4% by weight; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; solid lubricants, such as stearic acid, magnesium stearate; or calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and oil of theobroma; polyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers, such as the Tweens®; wetting agents such as sodium lauryl sulfate; coloring agents; flavoring agents; excipients; tableting agents; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer solutions. Excipients are described in Remington's Pharmaceutical Sciences, Mack Publishing Co. (19th edit. 1995); Modern Pharmaceutics, Vol. 7, Chapters 9 & 10, Banker & Rhodes (1979); Lieberman, et al, Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Pharmaceutical Dosage Forms, 2d (1976). Their selection will depend on secondary considerations like taste, cost, and shelf stability, etc. which are not critical for the purposes of the subject invention, and can be made without difficulty by those skilled in the art.
  • [0049]
    In one embodiment all of the dosage forms of the present invention are uniform in size prior to coating with the coating layers. The uniform size allows for uniform coating thickness and more uniform dissolution of the coating layers.
  • [0050]
    Enteric polymers are generally applied onto the unit dosage forms as solutions in organic or aqueous solvents. The solvents commonly employed as vehicles are water, methylene chloride, ethanol, methanol, isopropyl alcohol, acetone, ethyl acetate and combinations thereof. The choice of the solvent is based primarily on the solubility of the polymer, ease of evaporation, and viscosity of the solution.
  • [0051]
    Some polymers are also available as aqueous systems. These include Eudragit® L30D (methacrylic acid-ethyl acrylate ester copolymer marketed by Rohm-Haas GmBH, West Germany); Aquateric® (cellulose acetate phthalate-containing product marketed by FMC Corporation, Philadelphia, Pa.); and Coateric® (a polyvinyl acetate phthalate based product marketed by Colorcon, Inc., West Point, Pa.). Unlike organic solutions, these aqueous-based systems can be prepared at high concentration without encountering high viscosity. Also, these aqueous systems do not have the problems associated with the organic systems such as flammability, toxicity of the residual solvent in the dosage form, etc.
  • [0052]
    Coating can be achieved by methods known to one skilled in the art such as by using fluidized bed equipment, perforated pans, a regular pharmaceutical pan, compression coating, continuous or short spray methods, or by drenching. For example, a plasticized dispersion of coating polymer may be applied onto the tablet core comprising the therapeutic active agent by spraying using any suitable spray equipment known in the art. In one embodiment the solid unit dosage forms are coated by continuous spray methods. In one embodiment the outer coating layer is applied after the inner coating layer but before the inner coating layer is dried and/or cured. In yet another embodiment the outer coating layer is applied immediately, e.g. within seconds, after the inner coating layer is applied. If a shiny finish coat is desired on the solid dosage forms of the present invention, a small quantity of polyethylene glycol can be applied to the finished dosage form.
  • [0053]
    The following non-limiting examples provide typical formulations for compositions of the present invention.
  • EXAMPLE 1
  • [0054]
    A wet granulation of 5-ASA (active ingredient), lactose, and povidone is blended with talc, magnesium stearate, sodium starch glycolate, and colloidal silicon dioxide. The blend is compressed into approximately 1034 mg tablets containing 800 mg of the active ingredient on a standard pharmaceutical rotary tablet press.
  • [0055]
    An inner layer of an EUDRAGIT® S coating of 9.2 mg/cm2 dried coating (i.e. about 62 microns) is applied to the core tablets first by pouring a portion of the coating formula without pigments and then by spraying coating onto the tablets. The coating suspension sprayed onto the tablets contains approximately 62% by weight on a dry basis of Eudragit®0 S and is based in isopropyl alcohol and acetone with dibutylphthalate as the acting plasticizer.
  • [0056]
    An outer coating is either applied immediately following the application of the inner coating or once the inner coating has cured. The outer coating layer is sprayed onto the tablets to achieve of 4.1 mg/cm2 dried coating (i.e. about 28 microns). This coating suspension contains approximately 61% by weight on a dry basis of EUDRAGIT® S and L in a ratio of 3:2. It is based in isopropyl alcohol and acetone with dibutylphthalate as the acting plasticizer.
  • EXAMPLE 2
  • [0057]
    A wet granulation of 5-ASA (active ingredient), lactose, and povidone is blended with talc, magnesium stearate, sodium starch glycolate, and colloidal silicon dioxide. The blend is compressed into approximately 1570 mg tablets containing 1200 mg of the active ingredient on a standard pharmaceutical rotary tablet press.
  • [0058]
    An inner layer of an EUDRAGIT® S and L mixture of 8.8 mg/cm2 dried coating (i.e. about 60 microns) is applied to the core tablets first by pouring a portion of the coating formula without pigments and then by spraying coating onto the tablets. The coating suspension sprayed onto the tablets contains approximately 61% by weight on a dry basis of Eudragit® S and L in a ratio of 3:2 and is based in isopropyl alcohol and acetone with dibutylphthalate as the acting plasticizer.
  • [0059]
    An outer coating is applied immediately following the application of the inner coating or once the inner coating has cured. The outer coating layer is sprayed onto the tablets to achieve of 11.9 mg/cm2 dried coating (i.e. about 80 microns). This coating suspension contains approximately 38% by weight on a dry basis of EUDRAGIT® L and is based in isopropyl alcohol and acetone with triethyl citrate as the acting plasticizer.
  • EXAMPLE 3
  • [0060]
    A wet granulation of 5-ASA (active ingredient), lactose, and povidone is blended with talc, magnesium stearate, sodium starch glycolate, and colloidal silicon dioxide. The blend is compressed into approximately 690 mg tablets containing 500 mg of the active ingredient on a standard pharmaceutical rotary tablet press.
  • [0061]
    An inner layer of an EUDRAGIT® S coating of 15.6 mg/cm2 dried coating (i.e. about 105 microns) is applied to the core tablets first by pouring a portion of the coating formula without pigments and then by spraying coating onto the tablets. The coating suspension sprayed onto the tablets contains approximately 62% by weight on a dry basis of Eudragit® S and is based in isopropyl alcohol and acetone with dibutylphthalate as the acting plasticizer.
  • [0062]
    An outer coating is applied immediately following the application of the inner coating or once the inner coating has cured. The outer coating layer is a hydroxpropyl methylcellulose coating applied to a thickness of about 100 microns of dried coating according to the following formula:
    Component Weight per Tablet
    Dri-Klear1 3.7 g
    White Chroma-Tone2   1 g
    Water  48 g

    1Dri-Klear is a mixture of hydroxypropyl methylcellulose, polyethylene glycol, hydroxypropyl cellulose, and silicon dioxide, manufactured by CHR Hansen.

    2White Chroma-Tone is a mixture of titanium dioxide and hydroxypropyl methylcellulose, manufactured by CHR Hansen.
  • EXAMPLE 4
  • [0063]
    Core tablets are manufactured to the following formula:
    Component Weight per Tablet
    Ketoprofen   2 mg
    Lactose 4.96 mg
    Starch 0.80 mg
    polyvinylpyrrolidone (PVP) 0.16 mg
    Magnesium stearate  0.8 mg
  • [0064]
    An inner layer of an EUDRAGIT® S coating about 20 microns is applied to the core tablets by spraying coating of the following formula:
    Component
    EUDRAGIT ® S100 3 g
    Diethyl phthalate 0.75 ml
    Silicone fluid 200/20CS 0.75 ml
    Methanol 25 parts 100 ml
    Dichloromehtane 75 parts
  • [0065]
    An outer coating layer is applied to the core tablet and inner coating layer. The outer coating layer is a hydroxpropyl methylcellulose coating applied to a thickness of about 150 microns of dried coating according to the following formula:
    Component
    Dri-Klear3 3.7 g
    White Chroma-Tone4   1 g
    Water  48 g

    3Dri-Klear is a mixture of hydroxypropyl methylcellulose, polyethylene glycol, hydroxypropyl cellulose, and silicon dioxide, manufactured by CHR Hansen.

    4White Chroma-Tone is a mixture of titanium dioxide and hydroxypropyl methylcellulose, manufactured by CHR Hansen.
  • EXAMPLE 5
  • [0066]
    Applied to the core tablets described in Example 4 is an inner layer of an aqueous EUDRAGIT® L 30 D-55 coating of about 70 microns dried coating of the following formula:
    Component
    EUDRAGIT ® L 30 D-55 260 g
    Talc  39 g
    Polyethylene glycol 6000  16 g
    Water 345 g
  • [0067]
    An outer coating layer is then applied as a hydroxpropyl methylcellulose coating to a thickness of about 50 microns of dried coating according to the following formula:
    Component
    Dri-Klear5 3.7 g
    White Chroma-Tone6   1 g
    Water  48 g

    5Dri-Klear is a mixture of hydroxypropyl methylcellulose. polyethylene glycol, hydroxypropyl cellulose, and silicon dioxide, manufactured by CHR Hansen.

    6White Chroma-Tone is a mixture of titanium dioxide and hydroxypropyl methylcellulose, manufactured by CHR Hansen.
  • EXAMPLE 6
  • [0068]
    The following formulation is encapsulated within soft or hard gelatin capsules:
    Component Weight per Tablet
    Insulin   20 i.u. (c.a. 1 mg)
    Sodium 5-methoxy salicyclate 150.0 mg
    PEG 4000  3.5 mg
    PEG 600 187.5 mg
    Capsule fill wt   342 mg
  • [0069]
    Thereafter, the capsule is coated. An inner layer of an EUDRAGIT® S coating is applied to the capsules by spraying coating of the following formula to a thickness of about 100 microns dried coating:
    Component
    EUDRAGIT ® S100  70 g
    Triethyl citrate  14 g
    Acetone 283 g
    Isopropyl Alcohol 483 g
  • [0070]
    Following the application of the inner coating, an outer coating layer of an EUDRAGIT® S and L mixture at a ratio of 2:3 of about 20 microns is applied to the tablets by spraying a coating of the following formula:
    Component Weight per Tablet
    EUDRAGIT ® L100  42 g
    EUDRAGIT ® S100  28 g
    Triethyl citrate  14 g
    Acetone 283 g
    Isopropyl Alcohol 483 g
  • [0071]
    While particular embodiments of the present invention have been described, it will be obvious to those skilled in the art that various changes and modifications of the present invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4211777 *17 May 19788 Jul 1980Fisons LimitedCompositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4312806 *2 Mar 198126 Jan 1982G. D. Searle & Co.Method and compounds for treating inflammatory bowel disease
US4412992 *8 Jul 19811 Nov 1983Biorex Laboratories Limited2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4432966 *31 Aug 198221 Feb 1984Roussel-UclafCompressed tablets for disintegration in the colon comprising an active ingredient containing nucleus coated with a first layer containing microcrystalline cellulose which is coated with an enteric organic polymer coating
US4496553 *28 Nov 198329 Jan 1985Farmaceutisk Laboratorium Ferring A/SPharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4537887 *5 Oct 198327 Aug 1985Beecham Group LimitedPharmaceutical formulation
US4539198 *7 Jul 19833 Sep 1985Rowell Laboratories, Inc.Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4540685 *21 Dec 198210 Sep 1985Bauer Kurt HProcess for the production of readily soluble 5-aminosalicylic acid preparations, compositions and methods of use
US4552899 *9 Apr 198420 Oct 1992Analgesic AssociatesTitle not available
US4632921 *26 Jul 198530 Dec 1986Bauer Kurt HProcess for the production of readily soluble 5-aminosalicylic acid preparations
US4670112 *21 Nov 19852 Jun 1987Farmaceutisk Laboratorium Ferring A/SProcess for preparing p-amino phenols by electrolysis
US4678516 *9 Oct 19847 Jul 1987The Dow Chemical CompanySustained release dosage form based on highly plasticized cellulose ether gels
US4780318 *10 Jan 198525 Oct 1988Lejus Medical AktiebolagOral pharmaceutical composition
US4880794 *8 Jun 198714 Nov 1989Soren HalskovPharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
US4888179 *15 Jan 198819 Dec 1989Lejus Medical AktiebolagDiuretic composition
US4910021 *25 Nov 198620 Mar 1990R. P. Scherer CorporationTargeted enternal delivery system
US4980173 *26 Jun 198925 Dec 1990Farmaceutisk Laboratorium Ferring A/SPharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US5013727 *26 Jun 19897 May 1991Farmaceutisk Laboratorium Ferring A/SPharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US5018621 *16 Apr 199028 May 1991Connell Jr John J OCylindrical container and dispenser for spherical objects
US5026560 *14 Jan 198825 Jun 1991Takeda Chemical Industries, Ltd.Spherical granules having core and their production
US5053228 *13 Jul 19901 Oct 1991W. R. Grace & Co.-Conn.Polymeric temperature sensitive drug carrier
US5068110 *14 Jul 198926 Nov 1991Warner-Lambert CompanyStabilization of enteric coated dosage form
US5082651 *25 Apr 199021 Jan 1992Smith Kline & French Laboratories LimitedPharmaceutical compositions
US5171580 *18 Apr 199115 Dec 1992Boehringer Ingelheim Italia S.P.A.Orally-pharmaceutical preparations with colon selective delivery
US5175003 *6 Apr 199029 Dec 1992Biosytes Usa, Inc.Dual mechanism controlled release system for drug dosage forms
US5186943 *3 Jan 198916 Feb 1993Ss Pharmaceutical Co., Ltd.Compressed-molded preparations
US5217720 *8 Jul 19918 Jun 1993Shin-Etsu Chemical Co., Ltd.Coated solid medicament form having releasability in large intestine
US5270055 *24 Oct 198914 Dec 1993Nordmark Arzneimittel GmbhSolid pharmaceutical sustained-release form
US5294448 *22 Nov 199015 Mar 1994British Technology Group LimitedDelayed release formulations
US5316772 *2 Dec 199131 May 1994Solvay & Cie, S.A. (Societe Anonyme)Bilayered oral pharmaceutical composition with pH dependent release
US5342627 *12 Nov 199230 Aug 1994Glaxo Canada Inc.Controlled release device
US5401512 *21 Feb 199228 Mar 1995Rhodes; JohnDelayed release oral dosage forms for treatment of intestinal disorders
US5409711 *9 Apr 199125 Apr 1995Eurand International SpaPharmaceutical formulations
US5476667 *15 Oct 199119 Dec 1995Kabi Pharmacia AbMethod for drug formulation and a pharmaceutical composition
US5482718 *23 Mar 19949 Jan 1996Hoffmann-La Roche Inc.Colon-targeted delivery system
US5500227 *23 Nov 199319 Mar 1996Euro-Celtique, S.A.Immediate release tablet cores of insoluble drugs having sustained-release coating
US5519014 *17 Jun 199421 May 1996Borody; Thomas J.Treatment of non-inflammatory and non-infectious bowel disorders
US5536507 *24 Jun 199416 Jul 1996Bristol-Myers Squibb CompanyColonic drug delivery system
US5540945 *29 Dec 199430 Jul 1996Chugai Seiyaku Kabushiki KaishaPharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
US5541170 *10 Mar 199530 Jul 1996Tillotts Pharma AgOrally administrable pharmaceutical compositions
US5541171 *23 May 199530 Jul 1996Tillotts Pharma AgOrally administrable pharmaceutical composition
US5543155 *5 Dec 19946 Aug 1996Egis Gyogyszergyar Rt.Diffusion-osmotic controlled drug-release pharmaceutical composition and process for preparing same
US5580578 *27 Jul 19933 Dec 1996Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5629012 *26 May 199513 May 1997Farmaceutisk Laboratorium Ferring A/SProcess for producing suppositories by compression and suppositories obtained by the process
US5639476 *2 Jun 199517 Jun 1997Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5654004 *5 Nov 19935 Aug 1997Hisamitsu Pharmaceutical Co., Inc.Oral pharmaceutical preparation releasable in the lower digestive tract
US5656290 *17 May 199512 Aug 1997The Procter & Gamble CompanyBisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5656294 *7 Jun 199512 Aug 1997Cibus Pharmaceutical, Inc.Colonic delivery of drugs
US5656296 *7 Jun 199512 Aug 1997Warner-Lambert CompanyDual control sustained release drug delivery systems and methods for preparing same
US5668123 *30 Aug 199616 Sep 1997SynthelaboMethod of maintaining remission from venous ulcers with sulphasalazine and its metabolite
US5681584 *22 Mar 199628 Oct 1997Ciba-Geigy CorporationControlled release drug delivery device
US5686105 *17 May 199511 Nov 1997The Procter & Gamble CompanyPharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5686106 *17 May 199511 Nov 1997The Procter & Gamble CompanyPharmaceutical dosage form for colonic delivery
US5716648 *8 Jun 199410 Feb 1998Farmaceutisk Laboratorium Ferring A/SCompositions for use in the regulation of subnormal pH values in the intestinal tract and for treatment of bowel diseases
US5731302 *30 Sep 199624 Mar 1998Crinos Industria Farmacobiologica S.P.A.Stable aqueous suspensions of mesalazine
US5788987 *29 Jan 19974 Aug 1998Poli Industria Chimica SpaMethods for treating early morning pathologies
US5811121 *29 Jan 199722 Sep 1998Eastman Chemical CompanyPH-sensitive coatings based on cellulose acetoacetate
US5837277 *13 Sep 199617 Nov 1998Smithkline Beecham CorporationPalatable pharmaceutical compositions
US5895663 *31 Jul 199720 Apr 1999L. Perrigo CompanyPseudoephedrine hydrochloride extended-release tablets
US5900252 *6 Nov 19924 May 1999Eurand International S.P.A.Method for targeted and controlled release of drugs in the intestinal tract and more particularly in the colon
US5914132 *11 Oct 199622 Jun 1999The Procter & Gamble CompanyPharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5932249 *29 Jul 19943 Aug 1999Dr. Falk Pharma GmbhBudesonide pellets with a controlled released pattern and process for producing the same
US5985927 *22 Mar 199616 Nov 1999Kreutz; WernerMedicaments for the selective treatment of tumor tissues
US6004581 *20 Dec 199621 Dec 1999Farmaceutisk Laboratorium Ferring A/SModified release oral pharmaceutical composition and method for the treatment of bowel diseases
US6068856 *13 Mar 199830 May 2000Byk Gulden Chemische Fabrik GmbhOral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6187756 *28 Jan 200013 Feb 2001The Massachusetts Institute Of TechnologyComposition and methods for treatment of neurological disorders and neurodegenerative diseases
US6231888 *12 Nov 199815 May 2001Perio Products Ltd.Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
US6326364 *8 Feb 19994 Dec 2001Cedars-Sinai Medical CenterUse of 5-aminosalicylates as antimicrobial agents
US6365185 *26 Mar 19992 Apr 2002University Of CincinnatiSelf-destructing, controlled release peroral drug delivery system
US6383471 *6 Apr 19997 May 2002Lipocine, Inc.Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6551620 *16 Jul 200122 Apr 2003Dr. Falk Pharma GmbhPellet formulation for the treatment of the intestinal tract
US6632454 *9 Mar 200114 Oct 2003Roehm Gmbh & Co. KgMultilayer pharmaceutical product for release in the colon
US6645528 *23 Oct 200011 Nov 2003Acusphere, Inc.Porous drug matrices and methods of manufacture thereof
US6709678 *14 Aug 199723 Mar 2004Losan Pharma GmbhEasy to swallow oral medicament composition
US6773720 *8 Jun 200010 Aug 2004Cosmo S.P.A.Mesalazine controlled release oral pharmaceutical compositions
US6808616 *13 Dec 200226 Oct 2004Noveon Ip Holdings Corp.Process for the preparation of 5-aminosalicyclic acid
US6893662 *15 Nov 200117 May 2005The Procter & Gamble CompanyPharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6932983 *3 Nov 200023 Aug 2005Acusphere, Inc.Porous drug matrices and methods of manufacture thereof
US20010048965 *7 Feb 20016 Dec 2001Cherukuri Subraman RaoConfectionery compositions
US20020034541 *3 Jul 200121 Mar 2002Roberto ValducciOral solid pharmaceutical formulations with pH-dependent multiphasic release
US20020039594 *11 May 19984 Apr 2002Evan C. UngerSolid porous matrices and methods of making and using the same
US20020068088 *14 Aug 19976 Jun 2002Peter GruberEasy to swallow oral medicament composition
US20020155156 *18 Apr 200224 Oct 2002Nostrum Pharmaceuticals, Inc.Novel coating for a sustained release pharmaceutical composition
US20020192282 *9 Mar 200119 Dec 2002Thomas BeckertMultilayer pharmaceutical product for release in the colon
US20030099711 *29 Aug 200229 May 2003David MeadowsSustained release preparations
US20030138495 *11 Oct 200224 Jul 2003Jepsen Svenn KluverMethod for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and crohn's disease
US20030152627 *9 Mar 200114 Aug 2003Thomas BeckertMulti-particulate form of medicament, comprising at least two differently coated forms of pellet
US20030175349 *20 Mar 200218 Sep 2003Council Of Scientific And Industrial ResearchPharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20040022844 *28 Oct 20025 Feb 2004Steffen HasenzahlUse of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040096499 *29 Jul 200320 May 2004Navin VayaNovel dosage form
US20040096501 *29 Jul 200320 May 2004Navin VayaNovel drug delivery system
US20040121003 *19 Dec 200224 Jun 2004Acusphere, Inc.Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20040185097 *21 Jan 200423 Sep 2004Glenmark Pharmaceuticals Ltd.Controlled release modifying complex and pharmaceutical compositions thereof
US20040224017 *15 Mar 200411 Nov 2004Nirmal MulyeProcess for preparing sustained release tablets
US20040234601 *19 Apr 200425 Nov 2004Valerie LegrandMicroparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20050079216 *30 Jan 200314 Apr 2005Roehm Gmbh & Co. KgPharmaceutical dosage form and method for the production thereof
US20050090553 *24 Aug 200428 Apr 2005Shapiro Howard K.Compositions and method for treatment of chronic inflammatory diseases
US20050112201 *17 Sep 200426 May 2005Penwest Pharmaceuticals Co.Delayed release dosage forms
US20050196459 *24 Nov 20048 Sep 2005Flamel Technologies S.A.Carvedilol salts, anhydrates and/or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US848156527 Dec 20059 Jul 2013Eisai R&D Management Co., Ltd.Method for stabilizing anti-dementia drug
US850752725 Feb 201013 Aug 2013Eisai R & D Management Co., Ltd.Method for stabilizing anti-dementia drug
US88590053 Dec 201214 Oct 2014Intercontinental Great Brands LlcEnteric delivery of functional ingredients suitable for hot comestible applications
US908949211 Oct 201328 Jul 2015Warner Chilcott Company, LlcPharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US909551315 Jun 20074 Aug 2015Shin-Etsu Chemical Co., Ltd.Enteric coated granule and method for preparing the same
US20060246003 *29 Jun 20062 Nov 2006Eisai Co. Ltd.Composition containing anti-dementia drug
US20070184111 *3 Feb 20069 Aug 2007Pharmavite LlcHybrid tablet
US20070292509 *15 Jun 200720 Dec 2007Shin-Etsu Chemical Co., Ltd.Enteric coated granule and method for preparing the same
US20140141075 *21 Nov 201222 May 2014Warner Chilcott Company, Llc5-aminosalicylic acid capsule formulation
Classifications
U.S. Classification424/472
International ClassificationA61K47/30, A61K45/08, A61K9/28, A61K9/48, A61K9/32
Cooperative ClassificationA61K9/2886, A61K9/2846, A61K9/4891, A61K31/196, A61K9/284
European ClassificationA61K9/28H6B2, A61K9/28K, A61K9/48Z
Legal Events
DateCodeEventDescription
20 Aug 2009ASAssignment
Owner name: THE PROCTER & GAMBLE COMPANY, OHIO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DITTMAR, GREGORY PAUL;AMANTE, JOSEPH MICHAEL;CRONK, TONYRYAN;AND OTHERS;REEL/FRAME:023121/0943;SIGNING DATES FROM 20011031 TO 20011112
2 Nov 2009ASAssignment
Owner name: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTR
Free format text: SECURITY AGREEMENT;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:023456/0052
Effective date: 20091030
8 Jan 2010ASAssignment
Owner name: WARNER CHILCOTT COMPANY, LLC,PUERTO RICO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROCTER & GAMBLE COMPANY, THE;REEL/FRAME:023796/0417
Effective date: 20091030
Owner name: WARNER CHILCOTT COMPANY, LLC, PUERTO RICO
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PROCTER & GAMBLE COMPANY, THE;REEL/FRAME:023796/0417
Effective date: 20091030
29 Mar 2011ASAssignment
Owner name: WARNER CHILCOTT COMPANY LLC, PUERTO RICO
Free format text: RELEASE - REEL 023456, FRAME 0052;ASSIGNOR:CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT;REEL/FRAME:026042/0046
Effective date: 20110317
30 Mar 2011ASAssignment
Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, NO
Free format text: SECURITY AGREEMENT;ASSIGNOR:WARNER CHILCOTT COMPANY LLC;REEL/FRAME:026064/0607
Effective date: 20110317
31 Oct 2013ASAssignment
Owner name: WARNER CHILCOTT COMPANY, LLC, NEW JERSEY
Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:BANK OF AMERICA, N.A., AS COLLATERAL AGENT;REEL/FRAME:031531/0538
Effective date: 20131001
29 Sep 2016ASAssignment
Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, IR
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:040183/0129
Effective date: 20151231